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Abstract
Countless studies have demonstrated that many emergency-room visits and hospital admissions are drug-related and that a
significant proportion of these drug-related visits (DRVs) are preventable. It has not been previously studied which DRVs
could be prevented through enhanced monitoring of therapy. The objective of the study was to determine the incidence of
DRVs attributed to laboratory or physiologic abnormalities. Three authors independently performed comprehensive
searches in relevant health care databases using pre-determined search terms. Articles discussing DRV associated with
poisoning, substance abuse, or studied among existing in-patient populations were excluded. Study country, year, sample,
design, duration, DRV identification method, proportion of DRVs associated with laboratory or physiologic abnormalities
and associated medications were extracted. The three authors independently assessed selected relevant articles according
to the Strengthening the reporting of observational studies in epidemiology (STROBE) as applicable according to the
studies’ methodology. The initial literature search yielded a total of 1,524 articles of which 30 articles meeting inclusion
criteria and reporting sufficient laboratory or physiologic data were included in the overall analysis. Half employed
prospective methodologies, which included both chart review and patient interview; however, the overwhelming majority
of identified studies assessed only adverse drug reactions (ADRs) as a drug-related cause for DRV. The mean (range)
prevalence of DRVs found in all studies was 15.4% (0.44%–66.7%) of which an association with laboratory or physiologic
abnormalities could be attributed to a mean (range) of 29.4% (4.3%–78.1%) of cases. Most laboratory-associated DRVs could
be linked to immunosuppressant, antineoplastic, anticoagulant and diabetes therapy, while physiologic-associated DRVs
were attributed to cardiovascular therapies and NSAIDs. Significant proportions of laboratory and physiologic abnormalities
contribute to DRVs and are consistently linked to specific drugs. These therapies are potential targets for enhanced
medication monitoring initiatives to proactively avert potential DRVs.
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Introduction
Drug-related emergency room visits and hospital admissions
(DRVs) are a significant contributor to morbidity, mortality and
health care costs worldwide. While most documentation of the
problem has focused on DRVs attributed to adverse drug reactions
(ADRs), few researchers have explored other drug-related problem
(DRP) etiologies categorized within the pharmaceutical care
nosology, including inappropriate medication selection or dosing;
untreated symptoms or disease; drug interactions; and patient non-
adherence [1–5]. Features of patient populations at-risk for DRVs
have been consistently described (the elderly, those with impaired
cognition, dependent living situations, renal insufficiency, multiple
comorbidities or polypharmacy) as have the most common
offending therapies (antiplatelets, anticoagulants, non-steroidal
anti-inflammatory drugs (NSAIDS), diuretics, angiotensin con-
verting enzyme (ACE) inhibitors, opioids, and diabetes treatments)
[6–8].
Several broad recommendations for the reduction of prevent-
able DRVs have been proposed such as improving communication
between acute and ambulatory health care providers when
patients transition between care settings; conducting regular
review of prescription medications to avoid therapeutic duplica-
tion and to discontinue unnecessary drugs; advising patients to
frequent one community pharmacy and to discuss self-selection of
over-the-counter (OTC) and herbal therapy with a pharmacist or
physician [9–11]. Enhanced patient monitoring is also frequently
suggested. Baseline and follow-up assessment of renal function in
populations at-risk is most often cited, but improving the
monitoring of other specific laboratory values according to the
prescribed therapy (e.g. INR for anticoagulated patients, potassi-
um for diuretic-treated patients) is also advocated. Unfortunately,
low adherence to enhanced laboratory monitoring has been
demonstrated even when straightforward protocols are devised
[12–14]. Early detection of DRPs does not always require blood
testing; certain unfavourable medication responses manifesting
clinically may be recognized by straightforward patient assess-
ment. Simple vital sign evaluation is efficient and non-invasive and
therefore has potential for greater drug monitoring adherence.
Altered body physiology leading to harmful conditions and
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attributed to medication may be generally grouped within the
broader context of assignment of ADR-associated DRVs, but their
differentiation is important as distinct preventative measures may
be considered [15].
Our study objective is to estimate what proportion of total
DRVs are associated with laboratory or physiologic abnormalities
and therefore potentially be prevented with augmented monitor-
ing systems.
Methods
Searching
Three authors (KW, HH, AE) independently performed
comprehensive searches in relevant health care databases:
PubMed (1966-November Week 1 2011); Embase (1947-Novem-
ber Week 1 2011); EBM Reviews – Cochrane Central Register of
Controlled Trials (March 1996 to 3rd Quarter 2011); Web of
ScienceH (1960-November Week 1 2011); ScopusH (1996-Novem-
ber Week 1 2011); Science DirectH (1995-November Week 1
2011); and Latin American Caribbean Health Sciences Literature
(1982–2011). Predetermined search terms included key words and
phrases: ‘‘medication-related’’ or ‘‘drug-related’’; ‘‘hospitaliza-
tion’’; ‘‘emergency department’’; ‘‘visit’’ or ‘‘admission’’. No
language restrictions were applied. Search strategies were modified
to accommodate the controlled vocabulary in these databases.
References of retrieved articles were also hand-searched.
Abstracts of unpublished studies were identified by electronic
searching of available databases: International Pharmaceutical
Abstracts (1970-November Week 1, 2011) and Cumulative Index
to Nursing and Allied Health Literature (1982-November week 1,
2011) as well as by hand-searching International Society of
Pharmaceutical Outcomes Research, American College of Clinical
Pharmacy, American Society of Health-System Pharmacists,
Canadian Society of Hospital Pharmacy, European Society of
Clinical Pharmacy conference proceedings. Pre-determined search
terms were also applied to a general internet search using Google
Scholar.
Study Selection and Characteristics
The titles and abstracts of articles identified by the search were
screened for potential relevance. The duplicate article titles
identified among the searches by the three authors were
eliminated. Full-text of potentially relevant studies were retrieved
and considered eligible for inclusion according to pre-determined
selection criteria: 1) evaluation of drug-related presentation to an
ED for care; and/or 2) evaluation of a drug-related admission to
an inpatient setting; and 3) data reported in sufficient detail to
identify drug-related ED visit or hospitalization associated with
abnormal laboratory value/s or physiologic findings. Adverse
physiologic events were identified according to study documenta-
tion of specific clinical findings: 1) elevated or decreased systolic
blood pressure; 2) elevated or decreased heart rate; 3) elevated or
decreased respiratory rate; 4) elevated temperature or; 5) overt
bleeding event [15]. Studies of both adult and pediatric
populations were included. Articles were excluded if they: 1)
described ED visit or hospitalization due to illicit drug use or abuse
or intentional overdose; 2) described drug-related visits to
ambulatory or primary care settings; 3) described inpatient
detection of drug-related problems; or 4) were narrative reviews
or commentaries. Disagreements about inclusion were resolved in
author consensus meetings.
Validity Assessment
The three authors independently assessed selected relevant
articles according to the Strengthening the reporting of observa-
tional studies in epidemiology (STROBE) guide as applicable
according to the studies’ methodology to guide data extraction
[16]. The methods for identification and criteria for subsequent
characterization of a drug-related cause for emergency visit or
hospitalization; methods used to establish causal relationship
between the medication and observed outcome; tools for assessing
the preventability and the severity of the DRV were also assessed
to determine study quality and were graded as yes, no, unclear, or
not reported [17].
Data Abstraction
A standardized data extraction form was developed according
to the studies’ variables of interest: year of publication; country of
original; study setting, design; population; methods of data
collection and profession of data collectors; means for categorizing
potential drug-related visits and admissions; means for character-
izing preventability of drug-related visits and admissions; number
and nature of drug-related laboratory or physiologic abnormali-
ties; and finally the medications associated with these. Final
inclusion and exclusion decisions were then made by author
consensus.
Qualitative Data Synthesis
The methodological heterogeneity across studies including
identification and classification of DRPs precluded rigorous
quantitative assessment (meta-analysis) and so the study results
are described and evaluated qualitatively.
Results
Flow of Included Studies
The initial literature search yielded a total of 1,524 articles
(Figure 1). After reviewing the titles and abstracts, 1,099 articles
were excluded. These articles included duplicate titles (270),
description of DRVs due to illicit drug use or abuse (256); reports
of DRVs to ambulatory or primary care settings (187); research of
inpatient detection of DRPs (114); or were narrative reviews,
commentaries, editorials or letters (272). Four-hundred and
twenty-five studies remained for full text review, but despite an
English abstract, 14 were not available in English and 408 did not
provide sufficient details to determine laboratory or physiologic
abnormalities among the DRVs or admissions recorded. We
included 30 articles in the review.
Study Characteristics
Study characteristics of the included articles are described in
Table 1 [18–47]. A total number of 98,138,737 patient admissions
were evaluated in the included studies. The majority was
conducted among adult populations only and 10 specifically
assessed geriatric-DRVs. Only 1 study was performed in
pediatrics. The studies were conducted in health care settings
throughout the world, but predominantly in Europe, and spanned
over a wide range of evaluation time periods (2 weeks to 26 years).
Seven studies examined drug-related ED visits alone, while 13
involved drug-related hospital admission to particular patient care
units, usually internal medicine or related sub-specialty ward/s.
Half of the studies employed prospective methodologies that
included patient interview complemented by medical chart review.
Three reports estimated DRVs according to retrospective study of
national hospitalization databases.
Lab or Physiologic DRV - Systematic Review
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Adverse drug reaction-associated DRVs was the predominant
DRP evaluated (25/30) and combined with drug interaction-
associated DRVs in 4 of these studies. Five studies included all
DRPs when determining DRV etiology (Table 1). The WHO
definition for ADR (14/25) or a comparable one (5/25) was used
in the studies evaluating ADR-associated DRVs, but 2 did not
explicitly offer an ADR description. The 3 studies using patient
registries screened ADR-related DRVs according to recorded
ICD-9CM coding systems. All studies evaluating drug interactions
described their tertiary and secondary resources. When investiga-
tors considered all DRPs in determining DRVs (5/30), recognized
categories outlined by Hepler and Strand or Hallas were employed
[1], [48].
Nearly three quarters of the studies (25/30) mentioned a
causality assessment of the suspected DRV, of which the Naranjo
algorithm (9/30) and WHO algorithm (8/30) were the most
frequently used tools. Few studies (10/30) performed an assess-
ment of the severity of patient outcome resulting from DRVs and
only half of these descriptions were derived from a cited reference.
Eighteen studies did not report assessment of the preventability of
the DRVs they identified but 12 used recognized tools, such as
Hallas, Schumock and Thornton, and Guruwitz [48–50].
Thirteen studies reported that a clinician was involved in the
initial patient data screening and identification of the DRVs and
followed a secondary process of patient data evaluation to
subsequently validate the classification [21,24,25,29,30,32–
34,41–45]. In these reports, the study team was often multidisci-
plinary, and may have included physicians, pharmacists, or nurses.
Seven additional studies also described initial clinician determi-
nation of DRVs, but did not report additional independent case
adjudication [18,19,26,27,36,37,40]. Ten studies did not provide
information about who identified the DRVs
[20,22,23,28,31,35,38,39,46,47].
Data Synthesis
The mean (range) prevalence of DRVs found in these studies
was 15.4% (0.44%–66.7%) (Figure 2). In our pooled analysis, the
overall mean (range) proportion of these DRVs that could be
attributed to insufficient patient medication monitoring was 50.7%
(6.8%–100%) (Figure 3). We could identify laboratory abnormal-
ities in a mean of 29.4% (range 4.3%–78.1%) and findings of
adverse physiologic events in a mean of 23.3% (range 2.5%–
53.3%) contributing to the overall rate of DRVs as recorded by the
investigators. Even if studies sampling subjects from national or
hospital databases are censored and the evaluated patient
admissions in our analysis drops considerably from 98,138,737
to 29,570, mean estimated prevalence of overall DRVs, labora-
tory- and physiologic-related DRVs are not considerably altered
(16.5%, 31.9%, and 24.5%, respectively). There is also no
appreciable difference when retrospective (52.8%) and prospective
Figure 1. Flow chart of the process of identifying selected articles. This figure describes the outcomes of our outlined search strategy at
various stages of the systematic review. The three authors conducted structured searches in several databases, which yielded 1,524 citations. When
these titles were screened, 270 duplicate articles were identified and removed. Of the remaining titles, only 425 met our main inclusion criteria: 256
were excluded as they described illicit drug use or abuse-related DRV; 187 were DRV study in ambulatory or primary care populations; 114 were DRV
study in hospitalized populations; and 272 were reviews, commentaries, editorials or letters. Subsequently 381 full text articles assessed reported data
in insufficient detail to ascertain if documented DRVs could be associated with laboratory or physiologic abnormality and 14 abstracts were not
available in full-text English. The remaining 30 studies were included in the review.
doi:10.1371/journal.pone.0066803.g001
Lab or Physiologic DRV - Systematic Review
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(49.3%) studies are compared (Figure 4). When studies evaluating
laboratory- and physiologic-related DRV to the ED department
alone are compared to those only evaluating DRVs leading to
hospital admission, the incidence is somewhat higher (49.3% vs
44.9%, respectively, Figure 5). Observed mean estimates of the
incidence of laboratory- and physiologic-related DRVs varied
according to length of evaluation reported by (,3 months 55.8%;
3–6 months 46.9%; 7–11 months, 57.9%; 1–5 years, 43.2%; and
.5 years, 7.67%). When all DRP-related admissions are
considered, the overall incidence of DRV is 53.2% compared to
those studies evaluating only one DRP (ADRs, 48.3%) or two
DRPs (ADRs and DIs, 60.1%) contributing to the DRV (Figure 6).
The most common laboratory-related DRVs were abnormal-
ities in electrolytes (hyponatremia, hyper- and hypokalemia); blood
dyscrasias (anemia, neutropenia); metabolic disturbances (hyper-
and hypoglycemia); and acute renal failure. Overt bleeding events
(upper gastrointestinal bleeding, melena), hypotension and brady-
cardia were most frequently identified adverse physiologic events.
Laboratory-associated DRVs were most linked to anticoagulant,
antiplatelet, diabetes and immunosuppressant drugs, whereby
cardiovascular and NSAID analgesic therapeutic categories were
ranked highest for physiologic-associated DRVs. Culprit drug
therapy identified by investigators included loop diuretics, ACE
inhibitors, aspirin, wafarin, thiazide diuretics, digoxin, beta
blockers, sulphonylureas, and corticosteroids. Laboratory assess-
ment detected values outside recognized therapeutic ranges in
patients anticoagulated (elevated INR, n= 64), receiving digoxin
(n = 29), antiepileptic therapy (n= 23) and lithium (n= 5).
Discussion
This is the first systematic review of DRVs attributed to
complications associated with abnormalities in laboratory values
and adverse physiologic events. Prior work has also sought to
quantify the prevalence of monitoring problems contributing to
preventable hospital admissions and found median (range) rate of
22.2% (0–31.3%) across 5 papers [6]. In that study, the
characterization of a ‘‘monitoring problem’’ was not overtly
defined and presumably relied upon the interpretation of the
original authors of the studies in question. Our review is more
broad, in that we made an independent determination of
laboratory or physiologic abnormalities according to the detailed
DRV data reported by the investigators and considered studies
which did not necessarily ascribe preventability to its identified
DRVs.
We found that on average half of identified DRVs were
associated with patient morbidity that researchers linked with an
irregularity in a monitored parameter. Apparent evidence of these
laboratory and physiologic abnormalities contributing to DRV is
consistently reported across the studies we included in our analysis,
but incidences are highly variable (4.3%–100%). The broad range
is not dissimilar to study findings of DRV prevalence in general
Figure 2. Drug-Related Visits, overall pooled mean incidence and 95% CI.
doi:10.1371/journal.pone.0066803.g002
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and it is known that methodological factors impact observed rates
[51]. Our review similarly includes diverse study settings and
populations with considerations of all hospital admissions as well as
acute admissions to specific patient care areas or ED visits alone.
Just as identified by Leendertse et al, we too found that medical
chart screening yielded higher prevalence of DRVs and subse-
quent linkage to laboratory or physiologic abnormality than in our
three included studies of retrospective review of databases [51].
However, retrospective chart review usually reported only slightly
higher rates than the prospective chart reviews in our study.
Prospective data collection complemented by patient interview
may yield more conservative estimates as the subject is available to
inform or refute existence of a DRV whereas appropriate
characterization validation is unavailable in retrospective studies.
We examined investigator methods for detecting a DRV, how
causality was established between the untoward event and
offending drug therapy, as well as its preventability and severity.
Despite global interest in comprehensive evaluation of DRVs that
may be associated with any category of DRPs, a valid assessment
tool is lacking. Conversely, a number do exist specifically for
identification of suspected ADRs experienced by patients and were
employed by most researchers of the studies we included. We
found most studies applied a recognized causality assessment, but
few reported the severity or estimated preventability of the DRVs.
The ability to classify DRVs by preventability provides a
mechanism for clinicians to implement specific interventions and
subsequently evaluate their impact on patients and health systems.
Having said this, our review inherently emphasizes DRVs
associated with patient parameters whereby augmented monitor-
ing strategies could identify and address potential concerns before
the patient was faced with an ED visit or hospital admission. The
validity and reliability of DRV detection as reported in the
included studies is weak. The majority seemed to rely on a single
initial screening phase without further independent review.
Professional characteristics of the reviewer must also be considered
when exploring reliability in DRV detection. It has been
previously demonstrated that physicians overlook DRPs as a
cause for emergency department visits [52],[53].
Adverse drug reactions were the predominant DRP investigated
in our included studies. The ADR definition most often employed
was that of the WHO and defined as ‘‘any response to a drug
which is noxious and unintended occurring at human doses for
prophylaxis, diagnosis and therapy’’ [54]. A laboratory or
physiologic abnormality may arise from an exaggerated, but
unintended response (e.g. bradycardia with beta-blockers) or an
unexpected adverse reaction unrelated to conventional pharma-
cology (e.g. agranulocytosis with chlorpromazine). It is worthwhile
for future DRVs studies to incorporate alternate DRPs as sources
of laboratory and physiologic abnormalities as these can occur
from problems with medication adherence (e.g. low INR reported
in anticoagulated patient admitted for stroke); drug interaction
(e.g. subtherapeutic phenytoin value reported in patient receiving
Figure 3. Laboratory and Physiologic-Abnormality Associated DRV, overall pooled mean incidence and 95% CI.
doi:10.1371/journal.pone.0066803.g003
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concomitant antibiotic and admitted with seizure); or inappropri-
ate prescribing (e.g. increasing ACE inhibitor dose in the face of
hyperkalemia) [55]. Efforts to ameliorate deficiencies in laboratory
monitoring of specific drug therapies or of specific patients have
been described with few successes. Suboptimal laboratory
monitoring occurs under conditions when there is both failure to
conduct indicated tests at baseline or at appropriate follow-up
intervals and inadequate response when results are reported
[56].Patients’ prescribed therapy attributed to findings of inap-
propriate laboratory parameters contributing to DRVs in our
included studies are medications already known to possess risks of
organ-system toxicities or imbalances to electrolytes and metabolic
factors. While monitoring plans have already been outlined for a
number of these therapies, a host of practical implementation
barriers have been identified such as unclear assignment of
responsibility when multiple physicians are involved in care; lack
of alerts/reminders; physician fatigue and inaction due to
indiscriminant computer alters/reminders; and patient non-
adherence to instructions, to name just a few [57–59]. Team-
based and interdisciplinary approaches are needed to promote
appropriate medication monitoring. As highly accessible qualified
health care providers, pharmacists can assume shared responsi-
bility with prescribers to ensure appropriate laboratory assess-
ments are conducted and reviewed. When electronic clinical
decision support is in place, pharmacists improve patient care and
safety by reducing potentially inappropriate prescribed therapy
[60]. Studies have also shown that such pharmacist-led laboratory
alert prompting prescriber medication review can be cost-effective
[61]. When such patient data are not readily available, it is
reasonable to consider acquisition of relevant laboratory informa-
tion or physiologic assessments mandatory as a required element
for safe and responsible provision of therapy, not unlike
determination of a patient’s drug allergy status prior to prescrip-
tion processing and dispensing [62],[63].
Our review confirms that lack of adequate laboratory monitor-
ing contributes to patient morbidity; however our evaluation of the
occurrence of adverse physiologic events is a concept both not well
defined and perhaps consequently not previously explored.
Physical exam is a systematic process for investigating the body
and its function. Physical assessment skills necessary for health
professionals to conduct complete and accurate patient evaluations
have largely remained in the domain of physicians, nurses, and
even physiotherapists. Pharmacist roles and responsibilities to
ensure the optimal outcomes from the use of medication are
patient-centered and expanding in scope, which includes devel-
oping skills in percussion, palpation and auscultation [64],[65].
Combined with customary verbal patient information gathering
and inspection skills, pharmacists are increasingly equipped to
recognize adverse physiologic effects of drugs through vital sign
assessment and other straightforward physical exams. Observation
and measurement of abnormal vital signs can be early indicators of
Figure 4. Laboratory and Physiologic-Abnormality Associated DRV According to Study Methodology, mean incidence and 95% CI.
doi:10.1371/journal.pone.0066803.g004
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potential or actual DRPs and is an area of medication monitoring
to be explored in study of DRV prevention.
A number of limitations to our review warrant discussion.
Information for our analysis was derived from the published
reports and we did not contact authors of screened studies for
further data, which may diminish how representative our review is
in the context of other available literature. Furthermore, yield
from our search for any preliminary data (e.g. published
conference proceedings) and non-English language sources was
negligible, underscoring just some of the effects of publication bias
which we did not attempt to estimate or overcome with corrective
techniques (e.g. modeling, fail safe N). We did not explicitly use
‘‘adverse drug reaction’’ in our search strategy and although most
of our included studies assessed this particular DRV etiology, it is
possible we could have missed some evaluations of DRV due to
this or any other singular and specifically described DRP.
There has been little definitive work regarding adverse
physiologic events and in the past might be incorporated within
the context of a medication ADRs. We defined these events
according to one prior report that only encompassed abnormal
vital signs to which we added episodes of major or minor bleeding.
Our working definition likely underestimated the prevalence of
physiologic adverse events. For example, a number of studies
included in our review reported exacerbations of heart failure as a
Figure 5. Laboratory and Physiologic-Abnormality Associated DRV According to Patient Setting, mean incidence and 95% CI.
doi:10.1371/journal.pone.0066803.g005
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Figure 6. Laboratory and Physiologic-Abnormality Associated DRV According to Drug-Related Problem (DRP), mean incidence and
95% CI.
doi:10.1371/journal.pone.0066803.g006
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DRV. If the accompanying documentation did not specifically
refer to altered respiratory status (a vital sign), we did not
characterize that patient’s DRV as an adverse physiologic event. It
is possible that future interpretations may accommodate other
patient outcomes easily screened through simple physical assess-
ment or patient interview, such as altered level of consciousness or
peripheral edema. Finally, little can be concluded from our review
regarding the specific nature of DRVs in children as the majority
of included study populations were adults.
Conclusions
This review demonstrates laboratory abnormalities and adverse
physiologic events represent a large proportion of documented
drug-related emergency room visits and hospital admissions.
Current efforts to ameliorate deficiencies in patient medication
monitoring in this regard require augmentation with additional
multidisciplinary approaches and subsequent evaluation to deter-
mine if interventions actually impact patient outcomes and prevent
DRVs. Further work is also required to explore the potential for
early detection of adverse physiologic effects of drugs through
patient physical assessment by primary health care providers,
namely pharmacists.
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